We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Research Study Looking at Specific Tissue of the Umbilical Cord

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01166776
Recruitment Status : Completed
First Posted : July 21, 2010
Last Update Posted : August 22, 2016
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to isolate Umbilical cord Wharton's jelly matrix to be used as a scaffold for tissue regenerative applications, including avascular necrosis.

Condition or disease
Varices of Umbilical Cord

Detailed Description:
Our working hypothesis is that umbilical cord blood Wharton's Jelly matrix has all the biochemical and biomechanical characteristics needed in an ideal scaffold for tissue engineering. Accordingly, we expect matrix to support the growth and differentiation of transplanted mesenchymal stem cells. The first step in this effort is to isolate Wharton's Jelly matrix by decellularization. The second step will be to test the ability of this matrix to support the growth and differentiation of transplanted mesenchymal stem cells. The third step will be to pursue preliminary animal testing to study the ability of this matrix to support bone tissue regeneration in vivo.

Study Design

Study Type : Observational
Actual Enrollment : 64 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Decellularization of Umbilical Cord Wharton's Jelly for Tissue Regenerative Applications Including Avascular Necrosis
Study Start Date : June 2010
Primary Completion Date : April 2016
Study Completion Date : July 2016
Groups and Cohorts

Group/Cohort
Umbilical cord
To isolate Umbilical cord Wharton's jelly matrix to be used as a scaffold for tissue regenerative applications, including avascular necrosis.


Outcome Measures

Primary Outcome Measures :
  1. Isolation and decellularization of umbilical cord Wharton's jelly matrix [ Time Frame: Immediately upon delivery ]
    Use the Wharton's Jelly matrix as a scaffold, we should be able to remove the cellular components of Wharton's Jelly. This decellularization process will help decrease antigenicity and accordingly avoid allosensitization. Additionally, the matrix should be able to provide a 3 dimensional (3D) environment needed for biologic and geometric recellularization.


Secondary Outcome Measures :
  1. Study the ability of the isolated and decellularized matrix to support recellularization with mesenchymal stem cells and to support their growth and differentiation [ Time Frame: Within 24 hours ]
    Use the decellularized matrix for tissue regeneration purposes, it should be able to support recellularization with undifferentiated mesenchymal stem cells and help support their differentiation into different tissues, including bone or cartilage.


Biospecimen Retention:   Samples With DNA
umbilical cord tissue

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Pregnant women at time of delivery
Criteria

Inclusion Criteria:

  • Pregnant Women
  • 18 years of age or older
  • willing to donate umbilical cord units

Exclusion Criteria:

  • less than 18 years of age
  • Has Hepatitis or HIV
  • Considered High Risk
  • Scheduled for C-Section due to complications during current pregnancy
  • Delivered prior to Full Term
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01166776


Locations
United States, Kansas
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
United States, Missouri
Children's Mercy Hospital
Kansas City, Missouri, United States, 64108
Sponsors and Collaborators
University of Kansas Medical Center
Children's Mercy Hospital Kansas City
Investigators
Principal Investigator: Omar Aljitawi, MD University of Kansas Medical Center
More Information

Responsible Party: University of Kansas Medical Center
ClinicalTrials.gov Identifier: NCT01166776     History of Changes
Other Study ID Numbers: 12129
First Posted: July 21, 2010    Key Record Dates
Last Update Posted: August 22, 2016
Last Verified: August 2016

Keywords provided by University of Kansas Medical Center:
Wharton's jelly
umbilical cord
decellularization